SUMMARY The ability of plasma to support prostacyclin like activity from human umbilical arterial rings was studied in 17 patients with Henoch-Schonlein purpura and 17 controls matched for age and sex. Plasma from 13 of the 17 patients showed a diminished or absent ability to support prostacyclin like activity in vitro. Six patients whose plasma had a low or absent ability to support prostacyclin like activity showed evidence of inhibitory activity. Plasma from three of these patients also failed to preserve the effect of a stable prostacyclin like analogue (ZK36-374). The plasma concentration of prostacyclin metabolite and the serum concentration of thromboxane A2 metabolite, thromboxane B2, were measured simultaneously. The concentration of plasma prostacyclin metabolite in 10 of the 14 patients was decreased, and a positive correlation was found between the plasma prostacyclin metabolite values and the ability of the plasma to support prostacyclin like activity. There was no significant difference in the serum thromboxane A2 metabolite concentrations between the patients and controls. These data suggest that abnormalities of vascular prostaglandin metabolism are involved in the pathophysiology of Henoch-Schonlein purpura.
Henoch-Schonlein purpura is the most commonly encountered type of vasculitis in childhood. The skin lesions are the most obvious sign, but visceral involvement carries a more serious prognosis. In two thirds of patients arthritis and gastrointestinal involvement occur, and in a minority of patients, in addition, the central nervous system is involved. Renal involvement, however, is potentially the most serious manifestation as chronic renal impairment may develop.' 2 The aetiology and pathogenesis are obscure, but the primary manifestations are due to inflammation of small non-muscular vessels.3 Henoch-Schonlein purpura may follow exposure to drugs or allergens4 and is in many cases preceded by upper respiratory tract infection occasionally caused by group A P-haemolytic streptococci.3 None of these factors, however, have been confirmed to be of pathogenetic importance.
Increased number of data are now available about the possible role of vascular prostaglandins prostacyclin (PGI2), and thromboxane (TxA2) in the pathogenesis of other vasculopathies. PGI2 is an unstable substance with potent antiaggregatory and vasodilatory activity,5 synthesised from arachidonic acid by the vessel well cycloxygenase system.6 TxA2 is also an unstable endoperoxide with vasoconstricting and platelet aggregatory activity,7 derived from arachidonic acid predominantly by the platelet cycloxygenase system. 8 Remuzzi et al first showed deficient PGI2 production in the haemolytic uraemic syndrome and the related disorder of thrombotic thrombocytopenic purpura. Plasma taken from these patients had a low capacity to support PGI2 production in vitro from rat aortic rings.9 Reduced umbilical and placental vascular PGI2 has been observed in patients with severe pre-eclampsia. Saldeen et al have reported an increased concentration of TxA2 and PGI2 metabolites in patients with deep venous thrombosis," and increased TxA2 synthesis by platelets has been shown in Kawasaki disease.'2 We report our preliminary findings on various aspects of vascular prostaglandin metabolism in the acute phase of Henoch-Schonlein purpura.
Patients
Seventeen patients with Henoch-Schonlein purpura aged between 2 and 13 years (mean (SD) 5*7 (2-5) years) and 17 controls matched for age and sex were studied. The control children were free of renal, cardiovascular, pulmonary, and inflammatory disease and were admitted for minor surgical operations. All patients had the classical purpuric rash, and in 13 cases the skin lesions were associated with joint manifestations. One child had recurrent purpura, and none of the patients had hypertension. In eight cases gastrointestinal symptoms were observed, and this included one patient who required operative intervention for ileocolic intussusception. Three 
Results
Ability of plasma to support PGI2 like activity was reduced in 13 of the 17 patients with HenochSchonlein purpura studied. In five cases PSA was undetectable (Fig. 1) . The difference between the results of the patient group (21-3 (SD 20.5)%) and the control group (57.2 (SD 12-2)%) was significant (p<0.001). In addition, the results of those patients with abnormal urinalysis and gastrointestinal involvement (7.5 (SD 18 1)%) was significantly different from the results of those patients with neither of these manifestations, (32-3 (SD 23-5)%) (p<O.Ol).
Detection of inhibition against PGI2 like activity (PSAI). Plasma from six patients in which the PSA was low or absent was further investigated to detect PSAI. Less PGI2 like activity was produced by the unexhausted umbilical arterial rings when incubated with platelet poor plasma from the six patients than with either phosphate buffered saline or control platelet poor plasma (Table) . (p<005) (Fig. 2) . A positive correlation was found between PSA and PGI2m values (r=0-52, p<0.05).
There was no significant difference in serum TxB2 concentration between the 16 patients (11-4 (SD 9.4) ng/ml) and the control group (13.2 (SD 8.6) ng/ml). No significant correlation was found between the results of the tests on serum TxB2 and plasma PGI2m concentrations.
Discussion
It is well known that the pathological defect in Henoch-Schonlein purpura is that of a predominantly small vessel vasculitis. Abnormalities of vascular prostaglandin metabolism have been documented in other vasculopathies, particularly in the haemolytic uraemic syndrome. There are, however, no published reports of studies in HenochSchonlein purpura. Conceivably, after an endothelial insult, such as deposition of immune complexes, a defect of PGI2 generation may be present. We have shown that plasma from patients with Henoch-Schonlein purpura in the acute phase of the illness has a diminished or absent ability to support PG12 generation in vitro from human umbilical arterial rings. Absent or depressed PSA concentrations may theoretically be due to a number of causes, occurring singly or in combination. Firstly, a decreased ability of the plasma to stimulate PG12 production;9 secondly, the presence of inhibitory activity in the plasma either to the production'5 or to the effect of PGI2;22 and thirdly, rapid degradation of stimulated PGI2.23 All six patients in this study who had very low or absent concentrations of PSA, in whom further investigation was carried out, showed the presence of PSAI. The presence of PSAI may mean inhibitory activity against PGI2 production, inhibitory activity against PG12 effect, or increased PG12 degradation. To attempt to differentiate these possibilities we looked at the ability of test plasma to preserve the effect of a stable PGI2 analogue (ZK36-374) and found this to be absent in three of the six patients studied. The concentration of ZK36-374, although significantly higher than the physiological concentrations of PGI2m in both patients and controls, was chosen because a definite antiplatelet effect was desired. It would be interesting to undertake further studies using different concentrations of the PGI2 analogue; however, this was outwith the scope of this present study. On the basis of these data it would seem that in patients with low or absent concentrations of PSA inhibitory activity may exist to either PGI2 production or PGI2 effect.
We have also shown that most patients with Henoch-Schonlein purpura in this study had a decreased concentration of plasma PGI2 metabolite (PGI2m). It is of interest, however, that two patients showed a fairly high concentration of PGI2m in combination with a low or absent PSA concentration and plasma inhibitory activity to the effect of the stable PGI2 analogue. This would tend to confirm the presence of a circulating inhibitor to PG12 effect in these cases. These findings also show that platelet aggregation studies are more sensitive in detecting decreased PGI2 like activity of plasma than determination of PGI2m concentration.
We have found no significant difference in serum thromboxane (TxB2) concentrations between the patient group and the control population. Fur The above findings suggest the abnormality of PGI2 metabolism in Henoch-Schonlein purpura is rather complex and heterogenous. Further studies will be required to define the biochemical nature of the inhibitors and to establish whether low or absent PSA concentrations always reflect the presence of inhibitory activity and whether there is any evidence of rapid PGI2 degradation. It seems likely that these abnormalities, having been shown in yet another vasculitic syndrome, are most probably a secondary manifestation of endothelial damage. The disturbances, however, may well be of importance in extending the primary microvascular insult. 
